Guiyang Xintian Pharmaceutical Co Ltd (002873) — Working Capital to Net Assets Ratio
Guiyang Xintian Pharmaceutical Co Ltd (002873) has a Working Capital to Net Assets ratio of 12.5% as of March 2026. Working capital of CN¥156.90 Million (current assets of CN¥614.13 Million minus current liabilities of CN¥457.23 Million) is measured against net assets of CN¥1.26 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Guiyang Xintian Pharmaceutical Co Ltd balance sheet independence to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Guiyang Xintian Pharmaceutical Co Ltd Working Capital to Net Assets (2012–2025)
This chart shows how Guiyang Xintian Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the ratio stands at 12.5%, reflecting working capital of CN¥156.90 Million against net assets of CN¥1.26 Billion CNY. Check Guiyang Xintian Pharmaceutical Co Ltd (002873) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Guiyang Xintian Pharmaceutical Co Ltd (2012–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Guiyang Xintian Pharmaceutical Co Ltd from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Guiyang Xintian Pharmaceutical Co Ltd market cap and net worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 21.6% | CN¥270.84 Million | CN¥1.26 Billion | CN¥651.04 Million | CN¥380.20 Million | ▲ +10.2 pp |
| 2024 | 11.3% | CN¥135.43 Million | CN¥1.19 Billion | CN¥616.81 Million | CN¥481.38 Million | ▲ +4.1 pp |
| 2023 | 7.3% | CN¥81.00 Million | CN¥1.11 Billion | CN¥636.43 Million | CN¥555.42 Million | ▼ -2.9 pp |
| 2022 | 10.2% | CN¥115.24 Million | CN¥1.13 Billion | CN¥613.99 Million | CN¥498.75 Million | ▼ -6.1 pp |
| 2021 | 16.4% | CN¥145.59 Million | CN¥890.44 Million | CN¥586.83 Million | CN¥441.23 Million | ▼ -19.8 pp |
| 2020 | 36.1% | CN¥299.24 Million | CN¥828.30 Million | CN¥812.88 Million | CN¥513.64 Million | ▼ -0.2 pp |
| 2019 | 36.3% | CN¥257.36 Million | CN¥708.76 Million | CN¥590.06 Million | CN¥332.70 Million | ▼ -13.6 pp |
| 2018 | 49.9% | CN¥329.49 Million | CN¥660.59 Million | CN¥628.30 Million | CN¥298.81 Million | ▲ +1.9 pp |
| 2017 | 48.0% | CN¥298.60 Million | CN¥622.11 Million | CN¥504.05 Million | CN¥205.46 Million | ▲ +30.0 pp |
| 2016 | 18.0% | CN¥50.21 Million | CN¥279.21 Million | CN¥282.38 Million | CN¥232.18 Million | ▼ -1.0 pp |
| 2015 | 19.0% | CN¥43.07 Million | CN¥226.31 Million | CN¥234.10 Million | CN¥191.03 Million | ▼ -11.5 pp |
| 2014 | 30.5% | CN¥58.16 Million | CN¥190.50 Million | CN¥245.30 Million | CN¥187.14 Million | ▼ -0.4 pp |
| 2013 | 30.9% | CN¥48.67 Million | CN¥157.38 Million | CN¥216.88 Million | CN¥168.20 Million | ▼ -7.1 pp |
| 2012 | 38.0% | CN¥67.79 Million | CN¥178.44 Million | CN¥207.52 Million | CN¥139.73 Million | — |